Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;22(10):1397-405.
doi: 10.1016/j.cellsig.2010.03.018. Epub 2010 Apr 2.

C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity

Affiliations
Review

C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity

Urban Svajger et al. Cell Signal. 2010 Oct.

Abstract

The dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) is a type II C-type lectin whose expression is restricted to the most potent antigen-presenting cells (APCs), the dendritic cells (DCs). In recent years, DC-SIGN has gained an exponential increase in attention because of its involvement in multiple aspects of immune function. Besides being an adhesion molecule, particularly in binding ICAM-2 and ICAM-3, it is also crucial in recognizing several endogenous and exogenous antigens. Additionally, the intracellular domain of DC-SIGN includes molecular motifs, which enable the activation of signal transduction pathways involving Raf-1 and subsequent modulation of DC-maturation status, through direct modification of nuclear factor Nf-kappaB in DCs. Upon DC-SIGN engagement by mannose- or fucose-containing oligosaccharides, the latter leads to a tailored Toll-like receptor signalling, resulting in an altered DC-cytokine profile and skewing of Th1/Th2 responses. In this article, we will discuss recent advances on a broad perspective concerning DC-SIGN structure, signalling and immune function.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a. Schematic structure of DC-SIGN and amino-acid sequence alignment of the neck-repeat domain. The repeated hydrophobic amino-acid residues (hydrophobic heptad), crucial for tetramerization, is highlighted. Arrows point to the subtilisin site of digestion. b. DC-SIGN tetramerization through hydrophobic residues stacking in the neck-repeat domain (modified from Feinberg et al. [26]).
Fig. 2
Fig. 2
DC-SIGN signalling is ligand-dependent, activates Raf and down-stream mediators and contributes to modulation of signalling involved in DC activation. Activation of DC-SIGN with ManLam or gp120 leads to increased phosphorylation of Raf-1. This process requires a conformational change in Raf-1, that is mediated by small GTPase Ras. Raf-1 can then be phosphorylated at Ser338 by p21-activated kinases (Pak) and at Tyr340 and Tyr341 by kinases belonging to Src family, most probably Lyn and Syk. Activated Raf-1 is neccessary for phosphorylation of p50/p65 Nf-κB dimer in the nucleus, which is a prerequisite for later Nf-κB modification by histone acetyltransferases (HATs). The acetylation of Nf-κB is carried out at lysine residues 221 and 310 and this enables increased DNA binding and transcriptional activity by Nf-κB, leading to up-regulated IL-10 production. Salp15 binding to DC-SIGN leads to Raf-1 activation and modulated cytokine production without modulation of Nf-κB. In this manner, Raf-1 activates MEK, which without the activity of ERK, leads to increased degradation of IL-6 and TNF-α mRNA, as well as nucleosome remodelling at the IL-12p35 promoter.
Fig. 3
Fig. 3
HIV-1 interaction with DC-SIGN and subsequent events. The first CD4+ T-cell infection pathway through an HIV-1 escape mechanism is depicted with red arrows; an alternative 2nd pathway through DC infection is depicted with green arrows. Both pathways merge in HIV-1 trans transfer to CD4+ cells. DC-SIGN signalling modulation is presented in acid green.

References

    1. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Annu. Rev. Immunol. 2000;18:767. - PubMed
    1. Geijtenbeek T.B., Torensma R., van Vliet S.J., van Duijnhoven G.C., Adema G.J., van Kooyk Y., Figdor C.G. Cell. 2000;100(5):575. - PubMed
    1. Figdor C.G., van Kooyk Y., Adema G.J. Nat. Rev. Immunol. 2002;2(2):77. - PubMed
    1. Tacken P.J., de Vries I.J., Gijzen K., Joosten B., Wu D., Rother R.P., Faas S.J., Punt C.J., Torensma R., Adema G.J., Figdor C.G. Blood. 2005;106(4):1278. - PubMed
    1. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., Brimnes M.K., Moltedo B., Moran T.M., Steinman R.M. J. Exp. Med. 2004;199(6):815. - PMC - PubMed

Publication types

MeSH terms

Substances